Welcome! We regret to inform you that the Injury Board National News Desk has been discontinued. Feel free to browse around and enjoy our previously published articles, or visit The Injury Blog Network for the latest in personal injury news.

Pfizer Vows To Disclose Physician Payments

Posted by Jane Akre
Wednesday, February 11, 2009 10:53 AM EST
Category: Major Medical, Protecting Your Family
Tags: Pfizer, Conflict of Interest, FDA and Prescription Drugs, Biederman, Harvard, Emory, Nemeroff, Pharmaceutical Industry

Pfizer says it will become the first pharmaceutical company to disclose payments to doctors.



IMAGE SOURCE : Pfizer Web site 


Pfizer plans to become the first drugmaker to disclose the payments it makes to doctors and healthcare professionals who research or promote their drugs. 

Pfizer, the world’s biggest drugmaker says the payment disclosures will begin in early 2010 and will be posted on the www.pfizer.com Web site. 

Disclosures will include payments for speaking engagements and consulting fees, according to Reuters

Pfizer says the full disclosure is designed to boost trust in its drugs and the doctors promoting them.

Senator Charles Grassley (R-IA) has launched a probe into academic researchers and has found in many cases they underreport to their schools the private profits they are making from the pharmaceutical industry.

In the very public case of Dr. Joseph Biederman of Harvard and Dr. Charles Nemeroff of Emory University, neither psychiatrist was alleged to have fully disclosed to their university the amount of money they were collecting from the pharmaceutical industry, often while promoting the use of the drugs the companies manufactured.

"This makes Pfizer the first biopharmaceutical company to commit to reporting payments for conducting Phase I to Phase IV clinical trials, in addition to disclosing payments for speaking and consulting," Pfizer said in a release.

Last year, Pfizer says to Reuters, it made payments to many investigators researching their drugs in more than 280 studies.  

There is a loophole.

Technical writers who collaborate with an investigator to write an article will not be included in the disclosure but should be mentioned as a collaborator in the acknowledgments within in the article.

Critics have charged that ghostwriters, hired by the pharmaceutical industry, craft a story then the drug company attaches a well-known academic name as author, all for compensation.  The end result is to impress doctors and boost sales.  

IB’s San Antonio Blog reports that starting January 1st, the pharmaceutical industry has agreed to a voluntary moratorium which restricts drug company giveaways- such as Viagra pens and Lipitor coffee mugs. These “branded goodies” were meant to foster good will, but some say they may “subliminally” encourage doctors to prescribe more of the drugs. However, skeptics believe that the ban is a superficial measure that does nothing to curb the amount that drug companies spend each year trying to influence physicians.

Sen. Grassley is aggressively advocating transparency in the medical establishment and is promoting the Physician Payment Sunshine Act, which will require drug companies and medical device makers to disclose any payments of value above $500 to physicians.   #

No Comments

Comments for this article are closed.

About the National News Desk

Our mission is to seek the complete truth and provide a full and fair account of the events and issues that surround personal safety, accident prevention, and injury recovery.  We are committed to serving the public with honesty and integrity in these efforts.

Hurt in an accident? Contact an Injury Board member

Subscribe to Blog Updates

Enter your email address if you would like to receive email notifications when comments are made on this post.

Email address


RSS Feed

Add the National News Desk to your favorite RSS reader

Add to Google Reader Add to myYahoo Add to myMSN Add to Bloglines Add to Newsgator Add to Netvibes Add to Pageflakes